A company that aims to develop next generation radiopharmaceuticals using a copper radioisotope (64Cu) for both cancer diagnostic and therapeutic purposes.
Company name
Linqmed Inc.
Type of business
Medical(medical devices, drug discovery)
Representatives
Yukie Yoshii
Establishing a company
July 2022
Investment announcement date
January 2025
Capitalist
Jun Hayashi
HP
https://linqmed.co.jp/Phasing
Middle to Growth
